SCHEMBL17505652

SCHEMBL17505652

CC(=O)OC1CC2(O)C3CCC4CC(N5CCCC5)CCC4(C)C3CCC2(C)C1C1=CC(=O)OC1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.77
SMN1; SMN2 Q16637 3/20 0.77
RAB9A P51151 4/20 0.61
CYP2C19 P33261 2/20 0.61
NPC1 O15118 3/20 0.51
ATP1A1 P05023 5/20 0.51
ATP1B1 P05026 5/20 0.51
ATP1A2 P50993 5/20 0.51
PAX8 Q06710 3/20 0.51
ATP1A3 P13637 3/20 0.51
ATP1B2 P14415 3/20 0.51
ATP1B3 P54709 3/20 0.51
FXYD2 P54710 3/20 0.51
ATP1A4 Q13733 3/20 0.51
LMNA P02545 2/20 0.51
HIF1A Q16665 2/20 0.51
CYP3A4 P08684 1/20 0.51
TSHR P16473 1/20 0.51
ATP12A P54707 1/20 0.51
NOTCH1 P46531 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15526997 1.00 TP53 (0.77) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL15527657 1.00 TP53 (0.77) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL21833930 1.00 TP53 (0.77) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL15527660 1.00 TP53 (0.77) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL17505609 0.94 TP53 (0.71) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL17505608 0.94 TP53 (0.71) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL17505449 0.94 TP53 (0.75) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL21833880 0.94 TP53 (0.75) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL17505450 0.94 TP53 (0.75) TP53SMN1; SMN2RAB9ACYP2C19NPC1
SCHEMBL17505661 0.94 TP53 (0.75) TP53SMN1; SMN2RAB9ACYP2C19NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9676813-B2 Certain steroids and methods for using the same in the treatment of cancer NEUPHARMA, INC. (US) 2017-06-13 US claimed
US-20160039865-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2016-02-11 US claimed
US-11325940-B2 Certain chemical entities, compositions, and methods NEUPHARMA, INC. (US) 2022-05-10 US disclosed
US-20200102344-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2020-04-02 US disclosed
EP-3453713-A1 BUFADIENOLIDE COMPOUNDS SUBSTITUTED IN POSITION 3 BY AN AMINE GROUP FOR USE IN THE TREATMENT OF CANCER Neupharma, Inc. (US) 2019-03-13 EP disclosed
US-20170362271-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2017-12-21 US disclosed
US-9676813-B2 Certain steroids and methods for using the same in the treatment of cancer NEUPHARMA, INC. (US) 2017-06-13 US disclosed
US-20160039865-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2016-02-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039865-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TP53, VHL, SGMS2 TP53 1/4885SMN1; SMN2 3577/4885RAB9A 2171/4885
US-11325940-B2 Certain chemical entities, compositions, and methods TP53, VHL, SGMS2 TP53 1/4885SMN1; SMN2 3577/4885RAB9A 2171/4885
US-20170362271-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TP53, VHL, SGMS2 TP53 1/4885SMN1; SMN2 3577/4885RAB9A 2171/4885
US-20200102344-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TP53, VHL, SGMS2 TP53 1/4885SMN1; SMN2 3577/4885RAB9A 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.